E. Am

Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.

Sugarbaker Ph, E. Am, 1990 .

Therapeutic cancer vaccine development: will it ride the wave of new immunomodulatory agents?.

E. Am, Eggermont Am, 2011 .

An overview on the use of TNF-alpha: our experience with regional administration and developments towards new opportunities for systemic application.

E. Am, van Der Veen Ah, Teng Tl, 2000 .